FDA Expands Stelara Approval; Liver Cancer Blood Test; Pharmacotherapy for MASLD

(MedPage Today) -- The FDA expanded the approval of ustekinumab (Stelara) in Crohn's disease to include the treatment of kids as young as 2 years, Johnson & Johnson announced. High clinical remission rates (98%) at approximately 5 years were...
Source
MedPage Today
Opens original article in a new tab



